These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 2212119)

  • 1. Absence of estrogen receptors in dysplastic nevi and malignant melanoma.
    Lecavalier MA; From L; Gaid N
    J Am Acad Dermatol; 1990 Aug; 23(2 Pt 1):242-6. PubMed ID: 2212119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Proof of a Clinical Concept: Expression of Estrogen Alpha-, Beta-Receptors and G Protein-Coupled Estrogen Receptor 1 (GPER) in Histologically Assessed Common Nevi, Dysplastic Nevi and Melanomas.
    Spałkowska M; Dyduch G; Broniatowska E; Damiani G; Wojas-Pelc A
    Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833446
    [No Abstract]   [Full Text] [Related]  

  • 4. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
    Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
    Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A distinctive melanocytic lesion associated with melanoma-prone dysplastic naevus syndrome: the hybrid naevus.
    Schubert C; Parwaresch R; Rudolph P
    Virchows Arch; 2001 Feb; 438(2):166-72. PubMed ID: 11253119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of insulin-like growth factor-binding protein 2 in melanocytic lesions.
    Wang H; Shen SS; Wang H; Diwan AH; Zhang W; Fuller GN; Prieto VG
    J Cutan Pathol; 2003 Nov; 30(10):599-605. PubMed ID: 14744083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beclin 1 and LC3 autophagic gene expression in cutaneous melanocytic lesions.
    Miracco C; Cevenini G; Franchi A; Luzi P; Cosci E; Mourmouras V; Monciatti I; Mannucci S; Biagioli M; Toscano M; Moretti D; Lio R; Massi D
    Hum Pathol; 2010 Apr; 41(4):503-12. PubMed ID: 20004946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
    Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
    J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen and progesterone receptors in melanocytic lesions. Occurrence in patients with dysplastic nevus syndrome.
    Ellis DL; Wheeland RG; Solomon H
    Arch Dermatol; 1985 Oct; 121(10):1282-5. PubMed ID: 4037821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical expression of VEGF, HIF1-a, and PlGF in malignant melanomas and dysplastic nevi.
    Konstantina A; Lazaris AC; Ioannidis E; Liossi A; Aroni K
    Melanoma Res; 2011 Oct; 21(5):389-94. PubMed ID: 21876459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions.
    Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR
    Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas.
    Hussein MR; Roggero E; Sudilovsky EC; Tuthill RJ; Wood GS; Sudilovsky O
    Am J Dermatopathol; 2001 Aug; 23(4):308-14. PubMed ID: 11481522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma?
    Skender-Kalnenas TM; English DR; Heenan PJ
    J Am Acad Dermatol; 1995 Dec; 33(6):1000-7. PubMed ID: 7490345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanocytic lesions in a private pathology practice. Comparison of histologic features in different tumor types with particular reference to dysplastic nevi.
    Hastrup N; Hou-Jensen K
    APMIS; 1993 Nov; 101(11):845-50. PubMed ID: 8286092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions.
    Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G
    Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective look at dysplastic nevi. What were they in 1978 and how have they fared since?
    Cockerell CJ; Berson DS
    Am J Dermatopathol; 1985; 7 Suppl():93-7. PubMed ID: 3940095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oestrogen receptor-beta expression in melanocytic lesions.
    Schmidt AN; Nanney LB; Boyd AS; King LE; Ellis DL
    Exp Dermatol; 2006 Dec; 15(12):971-80. PubMed ID: 17083364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and distribution of transforming growth factor-alpha within melanocytic lesions.
    Nanney LB; Coffey RJ; Ellis DL
    J Invest Dermatol; 1994 Nov; 103(5):707-14. PubMed ID: 7963661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin D1 and D3 expression in melanocytic skin lesions.
    Alekseenko A; Wojas-Pelc A; Lis GJ; Furgał-Borzych A; Surówka G; Litwin JA
    Arch Dermatol Res; 2010 Sep; 302(7):545-50. PubMed ID: 20496072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TSLC1 expression discriminates cutaneous melanomas from dysplastic nevi.
    You Y; Wang SH; Zhang JF; Zheng SY
    Melanoma Res; 2012 Dec; 22(6):430-5. PubMed ID: 23047161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.